Preimplantation Genetic Testing Market to Grow with a CAGR of 8.20% through 2030

Rising Incidence of Genetic Disorders and Advancements in Genetic Screening Technologies are expected to drive the Global Preimplantation Genetic Testing Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Preimplantation Genetic Testing Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Preimplantation Genetic Testing Market stood at USD 655.30 Million in 2024 and is anticipated to grow with a CAGR of 8.20% in the forecast period, 2026-2030.

Preimplantation Genetic Testing (PGT) comprises a suite of advanced genetic diagnostic techniques employed in reproductive medicine to evaluate embryos for genetic abnormalities prior to uterine implantation during in vitro fertilization (IVF). The primary objective of PGT is to enhance pregnancy outcomes by minimizing the risk of transmitting genetic disorders, thereby supporting healthier offspring.

The global PGT market is poised for significant growth, underpinned by expanding healthcare infrastructure and increasing adoption of assisted reproductive technologies worldwide. Rising demand for IVF services, coupled with improvements in the accuracy and reliability of genetic testing methodologies, is further propelling market expansion. As a consumer-driven segment of the diagnostics industry, PGT contributes notably to the broader healthcare economy by enabling personalized fertility solutions. The market encompasses various testing categories, including Focuses on detecting numerical chromosomal abnormalities, particularly aneuploidies. Techniques widely adopted include fluorescence in situ hybridization (FISH), array comparative genomic hybridization (aCGH), and increasingly, next-generation sequencing (NGS). Targets identification of embryos free from specific inherited single-gene mutations, facilitating risk reduction for conditions such as cystic fibrosis, sickle cell anemia, and Huntington’s disease. Applied when parents carry chromosomal rearrangements (e.g., translocations, inversions) that risk producing embryos with imbalanced chromosomal content.

The adoption and growth trajectory of PGT vary significantly across geographies, influenced by healthcare infrastructure maturity, cultural perspectives on reproductive genetics, regulatory environments, and socioeconomic conditions. Developed markets with advanced healthcare ecosystems and higher disposable incomes exhibit stronger demand, supported by established fertility centers integrating PGT into routine IVF protocols. Simultaneously, rapid infrastructural development in emerging regions is expanding access, contributing to the globalization of the PGT market.

Leading market participants prioritize continuous technological innovation to enhance diagnostic accuracy and streamline patient experience. Strategic partnerships and collaborations are actively pursued to expand market reach and reinforce brand equity. Governments worldwide recognize PGT’s economic and social value, implementing policies and incentives such as subsidies or tax benefits to accelerate industry growth and encourage adoption of advanced testing modalities. There is also an increasing focus on patient-centered care models, emphasizing transparency and accessibility.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Preimplantation Genetic Testing Market”

The Global Preimplantation Genetic Testing Market is segmented into procedure, product, technology, application, end user, regional distribution, and company.

Based on its application, the aneuploidy screening segment has emerged as the predominant market leader, Aneuploidies, defined as the presence of an abnormal number of chromosomes in embryos, are a leading cause of early pregnancy loss and failed IVF cycles. Given that chromosomal abnormalities occur in a significant proportion of embryos particularly among women of advanced maternal age PGT-A has become an essential tool for identifying euploid embryos with normal chromosomal complements. This directly enhances implantation rates and live birth outcomes, making aneuploidy screening indispensable in fertility clinics globally.

PGT-A is widely integrated into routine IVF protocols, especially in developed markets with established assisted reproductive technology (ART) infrastructure. Clinics prioritize aneuploidy screening to increase efficiency, reduce cycle cancellations, and minimize emotional and financial burdens on patients. The universal relevance of aneuploidy screening, irrespective of specific genetic disease risk, underpins its broad adoption compared to more niche PGT-M or PGT-SR applications. Advances in genetic testing technologies such as next-generation sequencing (NGS) and array comparative genomic hybridization (aCGH) have significantly enhanced the resolution, accuracy, and turnaround times for aneuploidy screening. These innovations allow comprehensive chromosome screening in a cost-effective and scalable manner, enabling laboratories to process higher volumes of samples while delivering precise results. Consequently, clinics can offer more reliable embryo selection services, fueling demand for PGT-A.

Based on its end user, the hospital segment has emerged as the predominant market leader, Hospitals offer a holistic care environment that combines reproductive medicine, genetic counseling, and advanced laboratory services under one roof. This integration facilitates seamless coordination across specialties including embryologists, geneticists, fertility specialists, and obstetricians enhancing the quality and efficiency of PGT workflows. The availability of cutting-edge IVF units alongside molecular diagnostics labs allows hospitals to deliver end-to-end fertility care, making them preferred centers for patients requiring complex genetic screening. Hospitals typically serve a broad and diverse patient population, including high-risk fertility cases that require advanced genetic testing. Their capacity to manage complicated IVF cycles, recurrent pregnancy loss, and genetic disorder screening positions them as critical hubs for PGT deployment. Moreover, hospitals often cater to both insured and self-paying patients, expanding access across socio-economic segments.

Based on region, The Asia Pacific region is experiencing rapid market growth. Asia Pacific is experiencing a significant rise in infertility cases, fueled by lifestyle changes, environmental factors, and growing urbanization. Additionally, there is a notable trend of delayed parenthood as more women pursue higher education and careers, often opting to conceive later in life. This demographic shift increases the risk of chromosomal abnormalities, driving demand for PGT, especially aneuploidy screening (PGT-A), to improve IVF success rates.

Countries such as India, China, Japan, and South Korea are rapidly developing advanced fertility centers and IVF clinics equipped with cutting-edge genetic testing technologies. Investments in modern laboratory facilities, coupled with an increasing number of trained embryologists and genetic counselors, are making PGT more accessible. The rising number of fertility clinics offering integrated PGT services is a key growth enabler. There is increasing awareness among patients and healthcare providers about the benefits of genetic screening in reproductive medicine. Educational initiatives, patient advocacy groups, and improved genetic counseling services are contributing to higher acceptance of PGT as a critical component of fertility treatment protocols. This growing awareness is expanding the patient base and encouraging earlier adoption of PGT technologies.

Major companies operating in Global Preimplantation Genetic Testing Market are:

• California Pacific Medical Center (CPMC)
• CombiMatrix Corp
• CooperSurgical, Inc.
• F. Hoffmann-La Roche Ltd.
• Genea Limited
• Genesis Genetics
• Good Start Genetics, Inc.
• IGENOMIX
• Illumina, Inc.
• Invitae Corporation
• Laboratory Corporation of America Holdings

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Preimplantation Genetic Testing Market is poised for robust growth, driven by technological advancements, rising infertility rates, and increasing demand for personalized reproductive solutions. With expanding healthcare infrastructure, favorable regulatory support, and growing patient awareness across key regions, the market presents significant opportunities for innovation and investment. As PGT continues to evolve as a critical component of assisted reproductive technologies, stakeholders are well-positioned to capitalize on this expanding landscape by delivering enhanced diagnostic accuracy, improved clinical outcomes, and comprehensive patient-centered care”, said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Preimplantation Genetic Testing Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Procedure (Preimplantation Genetic Screening, Preimplantation Genetic Diagnosis), By Product (Reagents and Consumables, Instruments, Software), By Technology (Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescent In-Situ Hybridization (FISH), Others), By Application (Chromosomal Abnormalities, X-linked Diseases, Embryo Testing, Aneuploidy Screening, HLA Typing, Other), By End User (Fertility Centers, Hospitals, Diagnostic Centers, Research Centers and Academic Labs), By Region, & Competition, 2020-2030F”, has evaluated the future growth potential of Global Preimplantation Genetic Testing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Preimplantation Genetic Testing Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]